Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36
Lipoprotein(a) reduction was consistent with phase 1 results
Topline 48-week data expected in 2Q 2024
https://www.biospace.com/article/releases/silence-therapeutics-announces-positive-topline-36-week-data-from-ongoing-phase-2-study-of-zerlasiran-in-patients-with-high-lipoprotein-a-/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.